The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...
NIAID The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international ...
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback